Patents by Inventor Jeffrey M. Besterman
Jeffrey M. Besterman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8598168Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: GrantFiled: April 5, 2007Date of Patent: December 3, 2013Assignee: MethylGene Inc.Inventors: Oscar Moradei, Isabelle Paquin, Sylvie Frechette, Tammy Mallais, Simon Roy, Roger Machaalani, Arkadii Vaisburg, Jeffrey M Besterman, Pierre Tessier, David Smil, Silvana Leit, Robert Déziel
-
Publication number: 20120046331Abstract: This invention relates to new antifungal agents, compositions thereof, and methods for inhibiting the growth of fungi involved in infection and disease of keratinized tissue, such as onychomycosis. The invention also relates to new antifungal agents, compositions thereof, and methods for treating and/or preventing fungal infection and/or disease of keratinized tissue, such as onychomycosis. The invention further relates to a kit comprising said antifungal agent and use of said kit in treatment of fungal infection and/or disease of keratinized tissue, such as onychomycosis.Type: ApplicationFiled: August 19, 2011Publication date: February 23, 2012Inventor: Jeffrey M. Besterman
-
Patent number: 7868205Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: GrantFiled: September 24, 2004Date of Patent: January 11, 2011Assignee: MethylGene Inc.Inventors: Oscar Moradei, Isabelle Paquin, Silvana Leit, Sylvie Frechette, Arkadii Vaisburg, Jeffrey M. Besterman, Pierre Tessier, Tammy C. Mallais
-
Patent number: 7514556Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require a ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: GrantFiled: July 30, 2007Date of Patent: April 7, 2009Assignee: Methylgene Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Arkadii Vaisburg
-
Publication number: 20080132525Abstract: The invention relates to the inhibition of DNA methyltransferase isoforms DNMT1 and DNMT3b2. The invention provides compounds and methods for inhibiting DNMT1 and DNMT3b2.Type: ApplicationFiled: December 4, 2006Publication date: June 5, 2008Applicant: METHYLGENE INC.Inventors: Amal Wahhab, Jeffrey M. Besterman, Daniel Delorme, Isakovic Ljubomir, David Llewellyn, Jubrail Rahil, Oscar Saavedra, Robert Deziel
-
Publication number: 20080132459Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: ApplicationFiled: September 24, 2004Publication date: June 5, 2008Applicant: MethylGene, Inc.Inventors: Oscar Moradei, Isabelle Paquin, Silvana Leit, Sylvie Frechette, Arkadii Vaisburg, Jeffrey M. Besterman, Pierre Tessier, Tammy C. Mallais
-
Patent number: 7259172Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require a ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: GrantFiled: July 2, 2004Date of Patent: August 21, 2007Assignee: MethylGene Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Arkadii Vaisburg
-
Patent number: 7205285Abstract: The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not possess a ?-lactam pharmacophore. These new inhibitors are fully synthetic, allowing ready access to a wide variety of structurally related analogs. Certain embodiments of these new inhibitors also bind bacterial DD-peptidases, thus potentially acting both as ?-lactamase inhibitors and as antibiotics.Type: GrantFiled: July 28, 2003Date of Patent: April 17, 2007Assignee: Methylgene, Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Rex Pratt
-
Patent number: 7030103Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require a ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: GrantFiled: October 8, 2002Date of Patent: April 18, 2006Assignee: Methylgene, Inc.Inventors: Jeffrey M. Besterman, Daniel Delorme, Jubrail Rahil
-
Patent number: 6953783Abstract: The invention relates to the modulation of gene expression. In particular, the invention relates to compositions comprising antisense oligonucleotides which inhibit expression of a gene in operable association with protein effectors of a product of that gene, and methods of using the same. In addition, the invention relates to the modulation of mammalian gene expression regulated by methylation.Type: GrantFiled: October 19, 1999Date of Patent: October 11, 2005Assignee: MethylGene, Inc.Inventors: Jeffrey M. Besterman, Robert A. Macleod, William M. Siders, Zuomei Li
-
Patent number: 6921756Abstract: The invention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require a ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: GrantFiled: April 8, 2003Date of Patent: July 26, 2005Assignee: MethylGene, Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Arkadii Vaisburg
-
Patent number: 6884791Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel ?-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic ?-lactamase inhibitors presently available, and which do not require a ?-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: GrantFiled: November 22, 2002Date of Patent: April 26, 2005Assignee: MethylGene, Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Arkadii Vaisburg
-
Publication number: 20040082546Abstract: The invention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not require a &bgr;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: ApplicationFiled: April 8, 2003Publication date: April 29, 2004Applicant: MethylGene, Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Arkadii Vaisburg
-
Publication number: 20040072770Abstract: This invention relates to the inhibition of histone deacetylase (HDAC) expression and enzymatic activity. The invention provides methods and reagents for inhibiting HDAC-7 and HDAC-8 by inhibiting expression at the nucleic acid level or inhibiting enzymatic activity at the protein level.Type: ApplicationFiled: July 3, 2002Publication date: April 15, 2004Inventors: Jeffrey M. Besterman, Zuomei Li, Daniel Delorme, Claire Bonfils
-
Publication number: 20040059115Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not require a &bgr;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: ApplicationFiled: October 8, 2002Publication date: March 25, 2004Inventors: Jeffrey M. Besterman, Daniel Delorme, Jubrail Rahil
-
Publication number: 20040029836Abstract: The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not require a &bgr;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.Type: ApplicationFiled: November 22, 2002Publication date: February 12, 2004Inventors: Jeffrey M. Besterman, Jubrail Rahil, Arkadii Vaisburg
-
Patent number: 6608046Abstract: The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not possess &bgr;-lactam pharmacophore. These new inhibitors are fully synthetic, allowing ready access to a wide variety of structurally related analogs. Certain embodiments of these new inhibitors also bind bacterial DD-peptidases, thus potentially acting both as &bgr;-lactamase inhibitors and as antibiotics.Type: GrantFiled: September 1, 2000Date of Patent: August 19, 2003Assignee: MethylGene, Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Rex Pratt
-
Publication number: 20030152557Abstract: This invention relates to the inhibition of histone deacetylase (HDAC) expression and enzymatic activity. The invention provides methods and reagents for inhibiting HDAC-4 and HDAC-1 by inhibiting expression at the nucleic acid level or inhibiting enzymatic activity at the protein level.Type: ApplicationFiled: January 14, 2002Publication date: August 14, 2003Inventors: Jeffrey M. Besterman, Claire Bonfils, Zuomei Li, Soon Hyung Woo, Arkadii Vaisburg, Daniel Delorme, Marielle Fournel, Rico Lavoie
-
Publication number: 20030148970Abstract: This invention relates to the inhibition of histone deacetylase (HDAC) expression and enzymatic activity. The invention provides methods and reagents for inhibiting HDAC-4 and HDAC-1 by inhibiting expression at the nucleic acid level or inhibiting enzymatic activity at the protein level.Type: ApplicationFiled: January 14, 2002Publication date: August 7, 2003Inventors: Jeffrey M. Besterman, Claire Bonfils, Zuomei Li, Soon Hyung Woo, Arkadii Vaisburg, Daniel Delorme, Marielle Fournel, Rico Lavoie
-
Patent number: 6599889Abstract: The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not possess a &bgr;-lactam pharmacophore. These new inhibitors are fully synthetic, allowing ready access to a wide variety of structurally related analogs. Certain embodiments of these new inhibitors also bind bacterial DD-peptidases, thus potentially acting both as &bgr;-lactamase inhibitors and as antibiotics.Type: GrantFiled: March 1, 2001Date of Patent: July 29, 2003Assignee: MethylGere, Inc.Inventors: Jeffrey M. Besterman, Jubrail Rahil, Rex Pratt